Leo Pharma receives UK approval for Adtralza

Efforts to receive approvals for Leo Pharma's eczema treatment Adtralza are continuing, and have now been rewarded by permission to launch the drug on the UK market.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR

While Leo Pharma awaits news on the fate of Adtralza in the US in the wake of a rejection from the Food and Drug Administration (FDA) earlier in the year, the company has positive news from the United Kingdom.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading